Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for alleged violations of the Securities Exchange Act of 1934, focusing on misleading statements regarding the company's growth and performance during the specified Class Period [1][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company specializing in cataract treatment, with its main product being the RxSight Light Adjustable Lens system, which includes an intraocular light adjustable lens and a light delivery device [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight and its executives misrepresented the company's growth, stating that utilization was rising and that newer customer cohorts were adopting the technology at a comparable or faster rate than previous cohorts. In reality, the company faced challenges with its field organization, leading to slower adoption and declining utilization [4]. - The lawsuit highlights that incremental placements of light delivery devices did not result in the expected volume of lens procedures, undermining the company's growth model [4]. Impact of Disclosures - On April 2, 2025, RxSight reported a sequential decline in quarterly lens sales and reduced its full-year revenue guidance by approximately $24 million, resulting in a 38% drop in the stock price [5]. - Further disclosures on July 8, 2025, revealed a 45% sequential decline in light delivery device sales and a second consecutive quarter of declining lens sales, leading to another 38% decrease in stock price [6]. Legal Representation - The plaintiffs in the lawsuit are represented by Robbins Geller Rudman & Dowd LLP, a law firm with significant experience in prosecuting investor class actions related to financial fraud [7].

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false or misleading statements regarding its financial performance and product demand during the specified class period [7]. Allegation Details - The lawsuit claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization of its products [7]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [7]. Financial Impact - On July 8, 2025, RxSight reported preliminary second quarter financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [7]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [7]. - Following this announcement, RxSight's stock price fell nearly 38% [7]. Next Steps - Investors who purchased RxSight shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc., following a class action lawsuit filed on behalf of investors who acquired RxSight securities between May 7, 2024, and July 8, 2025 [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery, utilizing the Company's Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the stall in LDD sales to adoption challenges over recent quarters [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, and investors who purchased securities between May 7, 2024, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees [1][2] - Investors wishing to serve as lead plaintiff must file a motion with the Court by September 22, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that RxSight misrepresented the performance of its field organization and the adoption rates of newer customer cohorts, leading to inflated stock prices [4] - It is claimed that the actual utilization across the installed base was declining, contradicting the company's statements about growth and support [4]

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning RxSight business and prospects, resulting in its stock trading at inflated prices. ...

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, Inc. is a medical technology company based in Aliso Viejo, CA, specializing in light adjustable intraocular lenses (LAL) used in cataract surgery, with its system involving the Light Delivery Device (LDD) [2]. Legal Allegations - The lawsuit alleges that RxSight's management failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. The CEO attributed the sales stall to adoption challenges [4]. - Following this announcement, RxSight's shares dropped by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Accessibility StatementSkip Navigation NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https:// ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case in the U.S. District Court for the Central District of California, under the case caption Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Financial Performance - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors during the relevant period when the company promoted strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products, which contributed to its inability to meet previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second quarter financial results on July 8, 2025, which showed significant declines in sales and revenue, RxSight lowered its full year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The lawsuit notes that RxSight's stock price fell nearly 38% following the announcement of disappointing financial results and guidance adjustments [5].

Core Insights - The Brown Capital Management Small Company Fund experienced an 8.59% return in Q2 2025, underperforming the Russell 2000® Growth index which returned 11.97% [1] - The underperformance was primarily noted in the last few weeks of the quarter [1] Fund Performance - Small-cap US stocks rebounded in Q2 2025 after a challenging first quarter [1] - The fund's top five holdings were highlighted as key picks for 2025 [1] Company Highlight: RxSight, Inc. - RxSight, Inc. (NASDAQ:RXST) is a commercial-stage medical device company specializing in light-adjustable intraocular lenses for cataract surgery [2] - RxSight, Inc. had a one-month return of 9.66%, but its shares have lost 83.24% of their value over the past 52 weeks [2] - As of September 12, 2025, RxSight, Inc. stock closed at $9.31 per share, with a market capitalization of $380.928 million [2] Performance Detractors - RxSight, Inc. was noted as one of the detractors to the fund's performance in Q2 2025, alongside Bio-Techne (TECH) [3]